These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12921981

  • 1. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, Kanayama Y, Himeno S, Matsuzawa Y.
    Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
    [Abstract] [Full Text] [Related]

  • 2. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
    Matsunaga A, Furuyama M, Hashimoto T, Toyoda K, Ogino D, Hayasaka K.
    Clin Exp Nephrol; 2009 Dec; 13(6):659-62. PubMed ID: 19603250
    [Abstract] [Full Text] [Related]

  • 3. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
    Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T.
    Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
    [Abstract] [Full Text] [Related]

  • 4. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
    Chang CF, Lin CC, Chen JY, Yang AH, Shiao MS, Kao JT, Yang WC.
    Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J.
    Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
    [Abstract] [Full Text] [Related]

  • 6. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
    Ieiri N, Hotta O, Taguma Y.
    Am J Kidney Dis; 2003 Jan; 41(1):244-9. PubMed ID: 12500244
    [Abstract] [Full Text] [Related]

  • 7. Topics in lipoprotein glomerulopathy: an overview.
    Saito T, Matsunaga A, Ito K, Nakashima H.
    Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
    [Abstract] [Full Text] [Related]

  • 8. Lipoprotein glomerulopathy: a rare cause of steroid-resistant nephrotic syndrome in a child.
    Vala K, Shah K, Kapadia S, Khandelwal M, Jojera A, Soni S, Prajapati A, Saha A.
    CEN Case Rep; 2024 Oct; 13(5):403-407. PubMed ID: 38438730
    [Abstract] [Full Text] [Related]

  • 9. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
    Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Arakawa M, Gejyo F.
    Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
    [Abstract] [Full Text] [Related]

  • 10. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M, Kuroda Y, Terao M, Yaginuma T, Kawakami M, Kanazawa Y.
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [Abstract] [Full Text] [Related]

  • 11. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy.
    Oikawa S, Suzuki N, Sakuma E, Saito T, Namai K, Kotake H, Fujii Y, Toyota T.
    Am J Kidney Dis; 1991 Nov; 18(5):553-8. PubMed ID: 1951334
    [Abstract] [Full Text] [Related]

  • 12. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
    Zhang B, Liu ZH, Zeng CH, Zheng JM, Chen HP, Zhou H, Li LS.
    Chin Med J (Engl); 2005 Apr 05; 118(7):555-60. PubMed ID: 15820086
    [Abstract] [Full Text] [Related]

  • 13. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy.
    Konishi K, Saruta T, Kuramochi S, Oikawa S, Saito T, Han H, Matsunaga A, Sasaki J.
    Nephron; 1999 Apr 05; 83(3):214-8. PubMed ID: 10529627
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of a paediatric case of lipoprotein glomerulopathy.
    Koitabashi Y, Ikoma M, Miyahira T, Fujita R, Mio H, Ishida M, Shimizu K, Sakaguchi H.
    Pediatr Nephrol; 1990 Mar 05; 4(2):122-8. PubMed ID: 2397177
    [Abstract] [Full Text] [Related]

  • 15. Marked decrease in plasma apolipoprotein A-I and high density lipoprotein-cholesterol in a case with Werner syndrome.
    Kobayashi J, Murano S, Yokote K, Mori S, Matsunaga A, Sasaki J, Takahashi K, Bujo H, Saito Y.
    Clin Chim Acta; 2000 Mar 05; 293(1-2):63-73. PubMed ID: 10699423
    [Abstract] [Full Text] [Related]

  • 16. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 05; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 17. Lipoprotein glomerulopathy in China.
    Chen Y.
    Clin Exp Nephrol; 2014 Apr 05; 18(2):218-9. PubMed ID: 24165683
    [Abstract] [Full Text] [Related]

  • 18. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy.
    Cheung CY, Chan AO, Chan YH, Lee KC, Chan GP, Lau GT, Shek CC, Chau KF, Li CS.
    Hong Kong Med J; 2009 Feb 05; 15(1):57-60. PubMed ID: 19197098
    [Abstract] [Full Text] [Related]

  • 19. Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.
    Karube M, Nakabayashi K, Fujioka Y, Yoshihara K, Yamada A, Matsunaga A, Saito T.
    Clin Exp Nephrol; 2007 Jun 05; 11(2):174-179. PubMed ID: 17593519
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.